Renuvion Dermal System for Dermal Resurfacing

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-30

Study Completion Date

2021-05-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, single arm, evaluator-blind prospective study of up to 55 study subjects who are seeking a procedure to reduce the appearance of wrinkles and rhytides.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Market Lower Eyelid Treatment With Renuvion in Greece

NCT05605691

Skin Laxity

COMPLETED NA

Histological Evaluation of Human Skin Bx to Assess the Effects of APR Tx as an Adjunct Procedure in Facelift Surgery

NCT06243744

Skin Laxity Tissue Degeneration Tissue Breakdown +2 more

COMPLETED NA

Evaluation of Efficacy and Safety of the triLift™ System

NCT05773924

Skin Laxity Wrinkle

UNKNOWN NA

Clinical and Histological Evaluation of BTL-785F Non-invasive Treatment for Facial Rejuvenation

NCT05987917

Wrinkle

COMPLETED NA

Clinical Study To Evaluate Paired Treatment With An Alexandrite Laser And Radiofrequency Microneedling For Facial Aging

NCT05388604

Wrinkle Photoaging Dyschromia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, single arm, evaluator-blind prospective study of up to 55 study subjects who are seeking a procedure to reduce the appearance of wrinkles and rhytides. All study subjects will be treated with the Renuvion Dermal System.

The study population will consist of males and females, 30 years of age or older, requesting a procedure for the purpose of improving facial appearance by reducing facial wrinkles and rhytides. Those subjects who meet eligibility criteria and agree to provide written informed consent will be invited to participate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wrinkle Rhytides

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Subjects

Subjects will be treated with the Renuvion Dermal System.

Group Type EXPERIMENTAL

Renuvion Dermal System

Intervention Type DEVICE

The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renuvion Dermal System

The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects ≥30 years of age.
2. Subject is seeking improvement of facial appearance by reducing facial wrinkles and rhytides.
3. Subject with a facial wrinkle score rating of at least 4 on the FWS.
4. Subject with a Fitzpatrick Skin Scale score ≤III.
5. Subjects who are willing and able to take protocol allowed medications prescribed at investigator discretion which may include Keflex or Z-pack as an antibiotic, Acyclovir or Valtrex as an antiviral, Diflucan as an antifungal, Ativan or Valium for anxiety during treatment, Norco or Ultram for pain control during or post-procedure, Gabapentin, Tylenol with Codeine or NSAIDS for post-procedure pain control, and/or Antihistamines for itching during healing.
6. Subjects who are willing to have polycarbonate eye shields placed for study treatment.
7. Subject is willing and able to provide written informed consent.
8. Subject is willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, post-care instructions, and returning for follow-up visits.
9. Subject is willing to maintain baseline skin care regimen during study participation with the exception when protocol specified ointments, moisturizers, and cleansers are required during healing stage (through approximately the 30-day follow-up). Sunblock is required throughout the study starting on approximately day 10.
10. Subject is willing to release rights to study Sponsor for the use of the photos, including in potential publication.
11. Subject is willing to abstain from other facial cosmetic procedures through the 6-month follow-up visit; examples include, but are not limited to, laser or chemical re-surfacing, dermabrasion, neuromodulator and/or filler injections, aesthetic facial surgery, etc.

Exclusion Criteria

1. Subject with a Fitzpatrick Skin Scale score ≥IV.
2. Subject is pregnant or lactating.
3. Active HSV-1 or diabetes mellitus.
4. Active cut, wound, or infection on the skin of the face.
5. Subject has used, within 30 days prior to screening or plans to use during study participation, Accutane, Retinol, or any medication that can cause dermal hypersensitivity.
6. Subject has used, within 10 days prior to study treatment, aspirin or NSAIDs.
7. Subject has a history of autoimmune disease (excluding Hashimoto's thyroiditis).
8. Subject with a known bleeding disorder or who is on blood thinning medication that may be at risk for bleeding.
9. Subject has a known adverse reaction to lidocaine and/or epinephrine.
10. Subjects with active skin disease of the facial area or known connective tissue disease.
11. Subjects with known susceptibility to keloid formation or hypertrophic scarring.
12. Subjects with present cancerous or pre-cancerous lesions in the area to be treated.
13. Subject who, for any reason, suspects that they will not be able to complete the prescribed follow-up assessment(s).
14. Subject has had concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety and effectiveness of the study treatment method.
15. Subject is not willing to release rights to study Sponsor for the use of the photos, including in potential publication.
16. Subject is enrolled in another investigational (drug or device) clinical trial that can interfere with this study's assessments.
17. Subject has undergone a facelift procedure within 12 months prior to the screening visit.
18. Subject has received IPL, microneedling, or chemical peels within 3 months prior to the screening visit.
19. Subject has received microneedling with RF or any facial treatment with an energy-based device within 6 months prior to the screening visit.
20. Subject has received facial injections with BOTOX® or other toxins within 6 months prior to the screening visit.
21. Subject has received hyaluronic acid or calcium hydroxylapatite fillers within 4 months prior to the screening visit.
22. Subject who is a family member or employee of the investigator or sponsor.
23. Participation in any other investigational study within 30 days prior to consent.
24. Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes